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1. Introduction
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and close to
90% of all renal neoplasms. Renal cell carcinomas, by definition, are tumors that originate in
the renal cortex. These tumors are often asymptomatic, have diverse clinical manifestations,
and can be associated with hereditary syndromes. Surgery is the treatment of choice for
localized RCC. In localized RCC, partial nephrectomy for small tumors and radical nephrec‐
tomy for larger tumors continue to be the gold standard. Surgical practice has reduced
morbidity and has advanced toward more limited and less invasive resection approaches. In
addition, cytoreductive nephrectomy is often indicated before embarking on systemic
treatment in patients with metastatic disease.
In recent years, there has been a shift from radical nephrectomy toward more nephron-sparing
approaches. RCC still remains a predominantly surgical disease because RCCs are frequently
characterized as tumors that are resistant to chemotherapy and radiation. However, advances
in the treatment of metastatic RCC have evolved, primarily with biologic response modifiers.
The management of RCC has undergone the most significant transformation. Scientific
understanding of the molecular basis of cancer and the role of growth factors have resulted in
the identification of signaling pathways relevant in the pathogenesis of renal cell carcinoma.
This knowledge provided the impetus for developing new drugs that target and inhibit these
diff e rent pathways. Previously, systemic therapy for renal cancer has been limited to the use
of interleukin-2 and the off-label use of interferon. These drugs formulated an immunothera‐
peutic approach to the treatment of advanced renal cancer. Translational research and
participation of patients with advanced renal cell carcinoma in clinical trials have resulted in
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the approval of six systemic targeted therapies. These include sorafenib tosylate, sunitinib
malate, temsirolimus, everolimus, bevacizumab in combination with interferon, and most
recently, pazopanib. Each of these drugs has increased therapeutic options and appears to
prolong survival for patients with advanced renal cancer.
2. Biologic basis of targeted therapy
Recent advancements in the understanding of the genetics of RCC have led to a new patho‐
logical classification of five different subtypes of RCCs: clear cell, papillary, chromophobe,
collecting duct carcinoma (Bellini Duct tumor), and renal carcinoma unclassified (renal
medullary carcinoma). This classification is primarily based on cytologic appearance and the
cell origin in combination with growth pattern and genetic alterations [1].
The grading of RCC is based on the morphology of a neoplasm with hematoxylin and eosin
(H&E) staining on microscopy. The most popular and widely used system for grading RCC is
a nuclear grading system described by Fuhrman, Lasky, and Limas in 1982. This system
categorizes RCC into one of four grades based on nuclear characteristics and has been shown
to correlate with prognosis.
Adenocarcinomas represent the great majority (85%) of renal cell cancers. Adenocarcinomas
may be subdivided into clear cell renal carcinomas, the most common form of kidney cancer;
Many cases of clear cell carcinoma are linked to inactivation of the von Hippel-Lindau tumor
suppressor protein (pVHL), [2]. VHL is a 213 amino acid protein that polyubiquinates hypoxia-
inducible factor 1 alpha (HIF1alpha) which marks it for destruction by the cellular proteosome.
Normally, low oxygen conditions allow HIF1alpha to accumulate and bind to HIF1beta
thereby creating a complex that transcriptionally activates genes. In patients with aberrant
VHL, HIF1alpha is left to accumulate freely without degradation even under normal oxygen
conditions and thus the transcription of genes related to glucose metabolism, apoptosis,
angiogenesis and endothelial stabilization are abnormally promoted. This disordered response
to hypoxia activates over 100 HIF-responsive genes which include growth factors and their
receptors such as VEGF, platelet-derived growth factor (PDGF), and transforming growth
factor alpha/beta (TGF), [3].
1nactivation of the VHL gene is an early step in clear cell renal carcinogenesis, at least for those
tumors associated with VHL disease. Subsequent studies have shown that VHL inactivation
is also common in non-hereditary clear cell renal carcinoma. Approximately 50% of sporadic
clear cell renal carcinomas harbor somatic mutations affecting the maternal and paternal VHL
locus.
Another downstream effect of the VEGF receptor (VEGFR) pathway is the activation of PI3
kinase and Akt which in turn promote mTOR kinase [4]. mTOR is a central component of
intracellular pathways that promote tumor growth and proliferation, cellular metabolism and
is a mediator of the hypoxic response as an upstream activator of HIF1alpha. When mTOR
and raptor combine to form an activated complex, they phosphorylate and thus activate the
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eukaryotic translation initiation factor 4E binding protein-1 (eIF-4BP1) and ribosomal S6 kinase
(p70s6k). This leads to the synthesis of cellular proliferation proteins such as cyclin D1,
angiogenesis mediators such as VEGF, and hypoxia response regulators such as HIF1alpha [5].
3. Targeted therapies
Systematic studies of cell lines in which pVHL or HIF status has been manipulated suggest
that as many as 100 HIF-responsive genes might be dysregulated when pVHL is crippled [6].
A number of these genes encode proteins that are implicated in tumorigenesis. This makes
them amenable to pharmacologic attack. Evidence now indicates that targeting these HIF-
responsive genes can alter the natural history of human renal carcinoma.
Fortunately, a number of drugs have been identified that indirectly downregulate HIF protein
levels. One such drug, rapamycin, inhibits mTOR, which plays a critical role in the regulation
of protein translation. This in turn affects HIFα, which is very sensitive to changes in protein
translation due in part to its high metabolic turnover rate. Inhibitors of mammalian target of
rapamycin (mTOR) like rapamycin, downregulate HIF, [7].
4. Targeting HIF-responsive growth factors
4.1. Vascular endothelial growth factor
Clear cell renal carcinomas are notoriously angiogenic. Indeed, prior to the availability of
computed tomography, renal angiograms were often used to diagnose these tumors. Renal
carcinomas overproduce a variety of angiogenic moieties including vascular endothelial
growth factor (VEGF), the product of a HIF-responsive gene. In addition to promoting
angiogenesis, VEGF might suppress antitumor immune responses as well. It has also been
suggested that VEGF has direct stimulatory effects on renal carcinoma cells, although these
findings await further corroboration, [8, 9].
Several drugs that inhibit VEGF, or its kinase insert domain-containing receptor (KDR), have
activity against clear cell renal carcinomas. In a randomized phase II study, patients with
metastatic renal carcinoma who were treated with 10 mg/kg (but not 3 mg/kg) bevacizumab,
a neutralizing antibody against VEGF, exhibited a significant delay in time-to-disease pro‐
gression, [10]. Other unrelated KDR inhibitors such as SU11248 (sunitinib maleate),
BAY43-9006 (sorafenib), and AG-013736 also appear to have significant activity against this
tumor subtype, [11, 12].
5. VEGFR tyrosine kinase inhibitors
VEGF stimulates endothelial cell proliferation and survival. Immature blood vessels appear
to be exquisitely sensitive to VEGF withdrawal. In contrast, mature blood vessels are less
Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Targeted Therapies
http://dx.doi.org/10.5772/54856
147
sensitive to VEGF withdrawal because their endothelial cells are responsive to additional
survival factors such as platelet-derived growth factor (PDGF) released from surrounding
pericytes. Ongoing efforts to improve our understanding of the basic biology of RCC have
identified several potential targets for therapeutic modulation. One particularly promising
area of investigation is the role of VEGF in the pathogenesis of renal cell carcinoma. VEGF is
a tumor-secreted cytokine that plays an important role in both normal and tumor-associated
angiogenesis. VEGF exerts its biologic effect by binding to cell surface VEGF receptors, thereby
inducing dimerization and autophosphorylation of intracellular receptor tyrosine kinases,
leading to activation of downstream signal transduction elements. There are several forms of
VEGF receptors (VEGFR), but VEGFR-2 appears to be the main receptor responsible for the
proangiogenic effects of VEGF. The relevance of VEGF to tumor biology is supported by the
high incidence of von Hippel-Lindau tumor suppressor gene mutations in patients with RCC,
which subsequently leads to increases in VEGF expression. Receptor tyrosine kinases (RTKs)
play an integral role in the signaling cascade of VEGF and PDGF [12].
RTKs have an extracellular domain that binds to their respective ligand and an intracellular
domain that holds the tyrosine kinase responsible for downstream signaling. Upon ligand
binding, the RTKs dimerize or multimerize to induce a conformational change that allows ATP
binding resulting in autophosphorylation and transphosphorylation. These tyrosine domains
are then able to phosphorylate and activate various proteins in the downstream signal
transduction cascade.
6. Sunitinib
Sunitinib is an oral drug with inhibitory activity against several related protein tyrosine kinase
receptors, including the platelet-derived growth factor receptor (PDGFR)–ß, stem cell factor
receptor (KIT), and Fms-like tyrosine kinase-3, as well as the vascular endothelial growth factor
(VEGF) receptors 1, 2 and 3, [13]. Two initial phase II trials of sunitinib 50 mg/day for 4 weeks
followed by 2 weeks rest in 169 metastatic renal cell carcinoma (RCC) patients who had failed
previous cytokine-based therapy demonstrated an investigator-assessed objective response
rate of 45%, a median duration of response of 11.9 months, and a median progression-free
survival (PFS) of 8.4 months [14, 15]. Recently, a survival analysis of these patients was
reported, suggesting a trend for improved median overall survival (OS) with sunitinib therapy
(26.4 vs 21.8 months; hazard ratio: 0.821; 95% confidence interval: 0.673-1.001; P =.051.Based
on these data, sunitinib has emerged as a frontline standard of care for patients with metastatic
RCC. Common toxicities associated with sunitinib have included fatigue, hand-foot syndrome,
diarrhea, mucositis, hypertension and hypothyroidism. Cardiotoxicity has been reported and
thus monitoring may be required in patients with preexisting heart disease [16].
In a population-based retrospective analysis comparing patients treated in the IFN era (n=131)
versus those treated in the sunitinib era (n=69), the patients treated with first-line sunitinib had
an associated doubling in OS compared to those treated with interferon (17.3 versus 8.7
months, p=0.004) [17]. When adjusted for Memorial Sloan Kettering Cancer Center (MSKCC)
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prognostic criteria, the HR of death for sunitinib versus IFN was 0.049 (p=0.001). Even those
patients classified as having a poor prognosis by MSKCC criteria had a survival advantage.
Current treatment algorithm for patients with met (10.7 versus 4.1 months, p=0.0329), sug‐
gesting that use of sunitinib is beneficial in this population as well.
7. Sorafenib
Sorafenib is an oral multikinase inhibitor that inhibits vascular endothelial growth factor
(VEGF) receptors 1-3, platelet-derived growth factor receptor (PDGFR)–ß, and the serine
threonine kinase Raf-1 [18]. A phase III trial of sorafenib randomized 905 treatment-refractory
metastatic RCC patients to sorafenib 400 mg orally twice daily or placebo [19]. In the sorafenib
arm, a progression-free survival (PFS) advantage of 5.5 months vs 2.8 months was observed
(hazard ratio for disease progression: 0.44; 95% confidence interval: 0.35-0.55; P <.01). The
median overall survival was also increased for patients in the sorafenib group (19.3 vs 15.9
months) but did not reach prespecified statistical boundaries for significance. The common
toxicities experienced with sorafenib are similar to sunitinib except that the hand-foot syn‐
drome may be more pronounced and cardiotoxicity and fatigue appears to occur less fre‐
quently. Based on these data, sorafenib has been FDA approved and become a standard of care
for second-line treatment of mRCC after immunotherapy failure. However, a smaller, random‐
ized phase II of sorafenib vs interferon alfa-2b in 189 previously untreated metastatic RCC
patients failed to demonstrate a PFS advantage over IFN. Compared with interferon alfa-2b,
sorafenib did not significantly improve the median PFS (5.6 vs 5.7 months, respectively), [20].
Although the reason for the lack of significant effect when compared with interferon alfa-2b
in the frontline setting remains unclear, one possibility is that it is because of a weaker
inhibition of VEGF receptor compared with sunitinib. Although there may be patients in whom
sorafenib is a preferred initial agent because of the toxicity profile or other considerations,
sorafenib has largely been relegated to second-line and later therapy. The identification of
those patients for whom sorafenib would be the preferred frontline treatment is needed.
8. Mammalian Target of Rapamycin (mTOR) inhibitors
Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR), a molecule impli‐
cated in multiple tumor-promoting intracellular signaling pathways.
Activation of the mTOR protein, through cellular stimuli-triggered activation of the PI3K/Akt
pathway, can also result in HIF accumulation. mTOR phosphorylates and activates p70S6K,
which results in enhanced translation of certain proteins, including HIF. Activated HIF
translocates into the nucleus, where it triggers the transcription of a large number of hypoxia-
inducible genes; among these are the growth factors vascular endothelial growth factor (VEGF)
and PDGF. These growth factors interact with their respective cell-surface receptors, leading
to cell migration, proliferation, and permeability. Temsirolimus and everolimus bind to the
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FK506-binding protein; this resultant protein-drug complex inhibits the kinase activity of
mTOR within the mTORC1 complex.
Temsirolimus was initially evaluated for patients with mRCC in a randomized phase II study
of three different dose levels [21]. When patients were retrospectively stratified into MSKCC
prognostic risk groups, the poor risk group appeared to have a better than expected OS, leading
to further evaluation in this population.
The subsequent phase III trial with temsirolimus had a primary endpoint of OS. Six hundred
and twenty-six previously untreated patients with poor prognostic criteria were randomized
to temsirolimus 25mg IV weekly, IFN alpha 18 million units (MU) three times a week or
temsirolimus 15 mg IV weekly plus IFN 6 MU three times a week [22]. To be considered poor
risk, patients were required to have three or more of the following adverse risk features:
Karnofsky performance status less than 80%, lactate dehydrogenase over 1.5 times the upper
limit of normal, hemoglobin below the lower limit of normal, serum corrected calcium more
than 10 mg/dl, time from first diagnosis of RCC to start of therapy of less than a year and three
or more metastatic sites. Of patients included in this trial, 19% had nonclear cell or unknown
histology. Temsirolimus monotherapy demonstrated an OS advantage compared to IFN alpha
(10.9 months versus 7.3 months, log rank p<0.008). The objective response rates were 8.6% for
temsirolimus and 4.8% for IFN, which was not statistically significant. The median PFS for the
temsirolimus monotherapy arm and interferon arm was 3.8 months (95% confidence interval
(CI): 1.9–2.2) and 1.9 months (95% CI: 3.6–5.2), respectively. Common side effects include
fatigue, hypercholesteremia and hyperglycemia. Temsirolimus has become a first-line option
for patients with metastatic RCC of any histologic subtype, appropriately applied to patients
with poor prognostic criteria.
Another  mTOR  inhibitor,  everolimus  (RAD001)  has  recently  been  reported  to  improve
progression-free survival in a phase III trial of patients with mRCC who had progressed
on sunitinib, sorafenib or both [23]. These patients were randomized to receive either ev‐
erolimus 10mg orally daily or placebo and were stratified by the number of previous ty‐
rosine  kinase  inhibitors  (TKI)  and  MSKCC  'previously  treated'  risk  groups  (one  point
each for anemia, hypercalcemia, and Karnofsky performance status <80; 0 points=favora‐
ble, 1 point=intermediate, 2 +points=poor risk group). The primary endpoint was PFS and
in the everolimus and placebo groups it was 4.9 months and 1.87 months (p<0.0001), re‐
spectively.  The PFS benefit  was seen in all  three MSKCC risk groups.  Common side ef‐
fects  included asthenia,  anemia and stomatitis.  Up to 14% of  patients experienced some
form  of  pneumonitis.  OS  was  14.79  and  14.39  months  (p=0.117)  respectively,  however
crossover  to  everolimus  was  permitted  in  this  study.  One  hundred  and  six  patients
randomized to  placebo  crossed  over  to  receive  everolimus  after  initial  progression.  For
this group, the median PFS was 5.09 months, which is similar to the PFS of the original
everolimus group. This is the first agent tested in a second-line trial after initial TKI fail‐
ure to demonstrate benefit. US FDA approval has recently been granted.
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9. Axitinib (AG013736)
AG013736 is another orally bioavailable small-molecule TKI of VEGFR-2 and PDGFR-B that
has shown activity in metastatic RCC. Preclinical data from Inai and colleagues suggested that
AG013736 inhibited angiogenesis and caused regression of existing tumor vessels.A phase II
trial enrolled 62 treatment-refractory patients with RCC that had progressed on sorafenib [24].
They were treated with oral axitinib 5mg twice daily. Of 62 patients, 13 (21%) patients exhibited
a partial response and the median PFS was 7.4 months. Another phase II trial with axitinib
enrolled cytokine-refractory, nephrectomized patients and demonstrated a response rate of
44.2% and a median time to progression of 15.7 months (25]. Grade 1/2 toxicity included
hypertension (33%), fatigue (29%), nausea (29%), diarrhea (27%), hoarseness (19%), anorexia
(17%), and weight loss (15%). Grade 3/4 toxicity included hypertension (18%), diarrhea (6%),
fatigue (6%), blister (4%), and limb pain (4%). These studies confirm that AG-013736 produces
a substantial objective response rate in cytokine-refractory, metastatic RCC.
10. Pazopanib (GW786034)
Pazopanib hydrochloride is an oral, angiogenesis inhibitor targeting vascular endothelial
growth factor receptor, platelet-derived growth factor receptor, and c-kit. In October 2009, the
US Food and Drug Administration–approved pazopanib for the treatment of patients with
advanced renal cell carcinoma. In the international, multicenter, randomized, double-blind
trial, 435 patients were randomly assigned (2:1) to receive pazopanib (n = 290) or placebo (n =
145), [26]. The study demonstrated a median progression-free survival (the primary endpoint)
of 9.2 months in the pazopanib arm vs 4.2 months in the placebo arm (hazard ratio [HR]: 0.46;
P <.001). This effect was observed both in patients who had not received previous treatment
(HR: 0.40) as well as patients pretreated with cytokine therapy (HR: 0.54). The median duration
of responses was 13.5 months. The overall survival results were not mature yet and 40% of
patients died by the time of final data cut-off. Based on this study, the recommended dose of
pazopanib for the treatment of advanced renal cell carcinoma is 800 mg administered orally
once daily without food (at least 1 hour before or 2 hours after a meal).
11. BAY 73-4506
BAY 73-4506 is an orally active, potent multikinase inhibitor targeting both tumor cell
proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases
(VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (RAF and p38MAPK).
Previously untreated patients with predominantly clear cell RCC and measurable disease
according to RECIST were enrolled in this multicenter, open-label, phase II study. Eligibility
criteria included ECOG performance status 0–1, low or intermediate risk MSKCCC prognostic
profiles, and adequate bone marrow and organ function. Treatment consisted of BAY 73-4506
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160mg once daily on a 3 weeks on/1 week off schedule. The primary endpoint was overall
response rate. Preliminary efficacy data of the 33 patients evaluable for response show a 27%
partial response (PR) and a 42% stable disease (SD) rate [27].
12. Sequence of targeted therapy
Currently, we have the fortunate problem of having several agents demonstrating effica‐
cy in the first- and second-line setting, with a number of other small molecule inhibitors
that target VEGFR tyrosine kinase being evaluated in mRCC consistently showing activi‐
ty.  With similar  mechanisms of  action,  clinical  responses have been observed,  including
in  patients  that  have  previously  received TKI  therapy.  Part  of  the  challenge  in  moving
forward is  the  lack  of  understanding of  the  biologic  underpinnings  of  resistance  to  the
currently approved agents and uniform clinical definitions of what truly constitutes treat‐
ment resistance.
Studies combining targeted therapies are being performed with the known caveat that
combinations are associated with high financial cost and risk of increased toxicity due to
additive and overlapping side effect profiles. Rational combinations of active agents continue
to be evaluated. Currently, combinations of targeted therapy remain experimental and they
should only be employed in the context of a clinical trial.
Targeted agents are also being studied in the adjuvant setting for patients with resected
highrisk  RCC.  The  Adjuvant  Sorafenib  or  Sunitinib  for  Unfavorable  Renal  Carcinoma
(ASSURE) intergroup trial randomizes high-risk nephrectomized patients to 1 year of sor‐
afenib,  sunitinib  or  placebo  (estimated  enrolment:  1332,  primary  endpoint:  disease-free
survival (DFS)) (NCT00326898). Other trials such as the phase III sunitinib versus placebo
study for the treatment of patients at high risk of recurrent RCC (S-TRAC: estimated en‐
rolment 236, primary endpoint: DFS) (NCT00375674) and the sorafenib versus placebo tri‐
al in patients with resected intermediate or high-risk RCC (SORCE: estimated enrolment
1656,  primary  endpoint:  DFS)  (NCT00492258)  will  further  help  elucidate  the  effect  of
these agents in the adjuvant setting.
13. Combination therapy
One of the next directions in the therapy of advanced RCC involves the combination of several
targeted agents to better inhibit a single pathway at several different levels or inhibition at the
same level of several pathways mediating different effects. As combinations of targeted agents
undergo investigation, it will be critical for these combinations to demonstrate clinical benefit
above and beyond those of sequential monotherapy with the same agents, in order to justify
the added toxicity and risk. Thus, prospective data in this regard are critical, and some data
have recently emerged.
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Combinations of VEGF-targeting agents have undergone initial testing. Several combina‐
tions of these targeted agents were studied, including temsirolimus with either bevacizu‐
mab  or  sorafenib.  Bevacizumab  was  also  combined  with  sunitinib,  and  PTK787/
ZK222584. These combinations have frequently demonstrated enhanced toxicity, prevent‐
ing  the  use  of  the  maximum single-agent  doses.  However,  temsirolimus  and  bevacizu‐
mab in combination could be given at full doses of each agent without enhanced toxicity
and with encouraging clinical activity.
The combination of sorafenib and bevacizumab showed preliminary evidence of antitumor
activity, but the full doses of each agents were not reached due to dose-limiting toxicity related
primarily to hand-foot syndrome, functional stomatitis, anorexia, and fatigue.
Additional preclinical data have described potentially favorable immunomodulation with
sunitinib therapy. Such data may provide a rationale for combination strategies with immu‐
notherapy to optimize antitumor effect.
At this point, such combinations cannot be recommended for routine use outside of a clinical
trial setting.A greater understanding of the pleiotropic effects of targeted agents is needed to
rationally build combinations.
14. Future directions and conclusions
Surgery is the mainstay of therapy across renal cell carcinoma stages, and surgical innovation
has resulted in less invasive approaches to localized disease while preserving oncologic
efficacy. Renal cell carcinoma has become a model for solid tumors in which a better under‐
standing of biologic pathways has led to systemic therapies that have dramatically improved
patient outcomes. Given the availability of multiple treatment options, each with a slightly
different profile of risk and benefit, there are currently multiple options for therapy. The
approach to treatment requires appreciation of the risks and benefits of each of these agents,
as well as knowledge of the limitations of the current data.
The goal for every metastatic renal cell carcinoma patient upon presentation is to maximize
overall therapeutic benefit, meaning delaying for as long possible a lethal burden of disease
while maximizing quality of life and patient convenience.
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